000			01558 a2200469 4500
005			20250512030825.0
264		0	_c19851015
008			198510s 0 0 eng d
022			_a0167-594X
024	7		_a10.1007/BF02228889 _2doi
040			_aNLM _beng _cNLM
100	1		_aTaylor, S A
245	0	0	_aPhase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study. _h[electronic resource]
260			_bJournal of neuro-oncology _c1985
300			_a131-5 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAziridines _xtherapeutic use
650	0	4	_aAzirines _xtoxicity
650	0	4	_aBenzoquinones
650	0	4	_aBrain Neoplasms _xdrug therapy
650	0	4	_aCerebellar Neoplasms _xdrug therapy
650	0	4	_aCyclohexenes
650	0	4	_aDrug Evaluation
650	0	4	_aEpendymoma _xdrug therapy
650	0	4	_aFemale
650	0	4	_aGlioblastoma _xdrug therapy
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMedulloblastoma _xdrug therapy
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aOligodendroglioma _xdrug therapy
650	0	4	_aRisk
700	1		_aMcCracken, J D
700	1		_aEyre, H J
700	1		_aO'Bryan, R M
700	1		_aNeilan, B A
773	0		_tJournal of neuro-oncology _gvol. 3 _gno. 2 _gp. 131-5
856	4	0	_uhttps://doi.org/10.1007/BF02228889 _zAvailable from publisher's website
999			_c2999351 _d2999351